natgillin/translations-raw huggingface dataset:
Fatal Guillain-Barré syndrome has been reported in &lt; 1% of patients who received ipilimumab 3 mg/kg in combination with gp100.
Guillain-Barréov sindrom sa smrtnim ishodom zabilježen je u &lt; 1% bolesnika koji su primali ipilimumab u dozi od 3 mg/kg u kombinaciji s gp100.
Fatal hepatic failure has been reported in &lt; 1% of patients who received ipilimumab 3 mg/kg monotherapy.
Zatajenje jetre sa smrtnim ishodom zabilježeno je u &lt; 1% bolesnika koji su primali monoterapiju ipilimumabom u dozi od 3 mg/kg.
Fatal intracranial haemorrhages have occurred for trametinib in combination with dabrafenib in 1% (3/209) of patients in study MEK115306 and in &lt; 1% (3/350) of patients in study MEK116513.
Smrtonosna intrakranijalna krvarenja pojavila su se uz trametinib u kombinaciji s dabrafenibom u 1% (3/209) bolesnika u ispitivanju MEK115306 te u &lt; 1% (3/350) bolesnika u ispitivanju MEK116513.
Fatal intracranial haemorrhages have occurred for trametinib in combination with dabrafenib in 1% (3/209) of patients in study MEK115306 and in &lt; 1% (3/350) of patients in study MEK116513.
Smrtonosna intrakranijalna krvarenja uz trametinib u kombinaciji s dabrafenibom javila su se u 1% (3/209) bolesnika u ispitivanju MEK115306 te u &lt; 1% (3/350) bolesnika u ispitivanju MEK116513.
Fatal toxic epidermal necrolysis has been reported in &lt; 1% of patients who received ipilimumab in combination with gp100 (see section 5.1).
Smrtonosna toksična epidermalna nekroliza zabilježena je u &lt; 1% bolesnika koji su primali ipilimumab u kombinaciji s gp100 (vidjeti dio 5.1).
Fatalities due to gastrointestinal perforation have been reported in &lt; 1% of patients who received ipilimumab 3 mg/kg in combination with gp100.
Smrtni ishodi zbog gastrointestinalne perforacije zabilježeni su &lt; 1% bolesnika koji su primali ipilimumab u dozi od 3 mg/kg u kombinaciji s gp100.
Febrile neutropaenia (temperature ≥ 38.5°C and absolute neutrophil count &lt; 1,000/µL)
febrilna neutropenija (temperatura ≥ 38,5°C i apsolutni broj neutrofila &lt; 1000/µl)
Febrile neutropenia defined as ANC &lt; 1,000/mm3and fever
Febrilna neutropenija definirana kao ABN &lt; 1000/mm³ i vrućica
Febrile neutropenia occurred in &lt; 5% of patients treated with eribulin.
Febrilna neutropenija razvila se u &lt; 5% bolesnika liječenih eribulinom.
Female gender and higher CD4 counts ( &gt; 250/mm3 in adult females and &gt; 400/mm3 in adult males) at the initiation of nevirapine therapy are associated with a greater risk of hepatic adverse reactions if the patient has detectable plasma HIV-1 RNA - i.e. a concentration ≥ 50 copies/ml - at the initiation of nevirapine.
Žene i bolesnici s povišenim brojem CD4 ( &gt; 250/mm3 u odraslih žena i &gt; 400/mm3 u odraslih muškaraca) imaju na početku terapije nevirapinom i povišeni rizik jetrenih nuspojava ako pri tome bolesnici imaju HIV-1 RNK u plazmi – tj. koncentraciju ≥50 kopija/ml.
Feraccru should not be used in patients with inflammatory bowel disease (IBD) flare or in IBD- patients with haemoglobin (Hb) &lt; 9.5 g/dl.
Feraccru se ne smije koristiti u bolesnika s akutnom upalnom bolešću crijeva (IBD) ili u bolesnika s
Ferriprox and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p &gt; 0.05).
Ferriprox i deferoksamin bili su jednaki u poboljšanju stabilizacije ili redukcije opterećenja tijela željezom unatoč kontinuiranoj primjeni željeza u transfuzijama u ovih bolesnika (nije bilo razlike u udjelu bolesnika s negativnim trendom feritina u serumu između dviju liječenih skupina dobivene regresijskom analizom; p &gt; 0,05).
Fever ( &gt; 38°C)
vrućica ( &gt; 38°C)
Fever ( &gt; 38°C) axillary
Vrućica ( &gt; 38°C) mjereno aksilarno
Fever ( &gt; 39°C)
vrućica ( &gt; 39°C)
Fever ( &gt; 39°C) axillary
Vrućica ( &gt; 39°C) mjereno aksilarno
Fever &gt; 38°C
Vrućica
Fever &gt; 38°C
Vrućica &gt; 38°C
Fever &gt; 39.5°C, injection site reactions, including induration, local swelling at the injection site ( &gt; 50 mm)1
vrućica &gt; 39,5°C, reakcije na mjestu injekcije, uključujući otvrdnuće, lokalno oticanje na mjestu injekcije ( &gt; 50 mm)1
Fever &gt; 39°C
Vrućica &gt; 39°C
Few cases ( &lt; 0.2%) of acute pancreatitis have been reported during long­term clinical trials with Victoza.
Tijekom dugotrajnih kliničkih ispitivanja lijeka Victoza prijavljeno je nekoliko slučajeva ( &lt; 0,2%) akutnog pankreatitisa.
FF and FP both increased the percentage of 24 hour rescue free periods by 14.8% (95% CI 6.9, 22.7, p &lt; 0.001) and 17.9% (95% CI 10.0, 25.7, p &lt; 0.001) respectively versus placebo.
Primjena flutikazonfuroata povećala je postotak 24-satnih razdoblja bez terapije za 14,8% (95% CI 6,9; 22,7, p &lt; 0,001), a primjena flutikazonpropionata za 17,9% (95% CI 10,0; 25,7, p &lt; 0,001) u odnosu na placebo.
Fidaxomicin and OP-1118 levels were approximately 2 times higher in patients ≥ 65 years compared to patients &lt; 65 years.
Koncentracije fidaksomicina i OP-1118 bile su približno dvaput veće u bolesnika u dobi od 65 ili više godina u usporedbi s bolesnicima mlađima od 65 godina.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. „odds reduction“) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (od engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. „odds reduction“) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favour of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (od engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favour of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel plus ASA group and 21.7% in the group treated with ASA alone reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Primarni ishod dostiglo je 15,0% bolesnika u skupini s klopidogrelom plus ASK te 21,7% u skupini samo s ASK, što predstavlja apsolutno smanjenje od 6,7% i smanjenje šansi (od engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), uglavnom povezano sa smanjenjem okluzija u koronarnim arterijama povezanih s infarktom.
Fifteen percent (15.0%) of patients in the clopidogrel plus ASA group and 21.7% in the group treated with ASA alone reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p &lt; 0.001), mainly related to a reduction in occluded infarct-related arteries.
Primarni ishod dostiglo je 15,0% bolesnika u skupini s klopidogrelom uz ASK te 21,7% u skupini samo s ASK, što predstavlja apsolutno smanjenje od 6,7% i smanjenje šansi od 36% u korist klopidogrela (95% CI: 24, 47%; p &lt; 0,001), uglavnom povezano sa smanjenjem okluzija u koronarnim arterijama povezanih s infarktom.
Fifty out of seventy five (67%) tocilizumab treated patients had a haemoglobin &lt; LLN baseline.
Pedeset od sedamdeset i pet bolesnika (67%) liječenih tocilizumabom na početku ispitivanja imalo je razinu hemoglobina manju od donje granice normale.
Fifty-three paediatric patients aged 2 to &lt; 18 years were treated with voriconazole in two prospective, open- label, non-comparative, multi-center clinical trials.
Vorikonazolom je liječeno 53 pedijatrijskih bolesnika u dobi od 2 do &lt; 18 godina u dva prospektivna, otvorena, nekomparativna, multicentrična klinička ispitivanja.
Fifty-three paediatric patients aged 2 to &lt; 18 years were treated with voriconazole in two prospective, open-label, non-comparative, multi-center clinical trials.
Vorikonazolom je liječeno 53 pedijatrijskih bolesnika u dobi od 2 do &lt; 18 godina u dva prospektivna, otvorena, nekomparativna, multicentrična klinička ispitivanja.
Filgrastim administration should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/L.
Poraste li broj leukocita na &gt; 70 x 109/l, filgrastim treba obustaviti ili njegovu dozu smanjiti.
Filgrastim administration should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/l.
Poraste li broj leukocita na &gt; 70 x109/l, filgrastim treba obustaviti ili njegovu dozu smanjiti.
Filgrastim administration should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/L.
Primjenu filgrastima potrebno je prekinuti ili smanjiti dozu lijeka ako se broj leukocita poveća na &gt; 70 x109/l.
Final adult height was available for 14 of those children and demonstrated that 12 continued to show height deficits &gt; 15 percentiles, 10 to 12 years after the end of treatment.
Konačna visina u odrasloj dobi bila je dostupna za 14 navedene djece te je za njih 12 pokazala deficit rasta &gt; 15 percentila, 10 do 12 godina nakon završetka liječenja.
Final adult height was available for 14 of those children and demonstrated that 12 continued to show height deficits &gt; 15 percentiles, 10 to 12 years after the end of treatment.
Konačna visina u odrasloj dobi bila je dostupna za 14 navedene djece te se pokazalo da njih 12 i dalje ima deficite rasta za &gt; 15 percentila, 10 do 12 godina nakon završetka liječenja.
Final adult height was available for 14 of those children and show that 12 continued to have height deficits &gt; 15 percentiles, 10 to 12 years after the end of treatment.
Konačna visina u odrasloj dobi bila je dostupna za 14 navedene djece te se pokazalo da njih 12 i dalje ima deficite rasta za &gt; 15 percentila, 10 do 12 godina nakon završetka liječenja.
Final adult height was available for 14 of those children and show that 12 continued to have height deficits &gt; 15 percentiles, 10 to 12 years after the end of treatment.
Konačna visina u odrasloj dobi bila je dostupna za 14 od te djece i pokazala je da ih je 12 nastavilo imati deficit visine &gt; 15 percentila 10 do 12 godina nakon kraja liječenja.
Fine Particle Mass &lt; 5 µm [mg±SD]
Doza koja se može udahnuti &lt; 5 µm [mg±SD]
Fingolimod and fingolimod phosphate are highly protein bound ( &gt; 99%).
Fingolimod i fingolimodfosfat u velikoj mjeri vežu se za proteine plazme ( &gt; 99%).
Fingolimod phosphate has a smaller uptake in blood cells of &lt; 17%.
Unos fingolimodfosfata u krvne stanice iznosi &lt; 17%.
Fipronil sulfone is produced on the haircoat (mean concentrations &lt; 16 % of fipronil during the first month after treatment).
Fipronil sulfon se izlučuje na dlaci (prosječne koncentracije &lt; 16 % fipronila tijekom prvih mjesec dana nakon tretmana).
First fall to &lt; 0.5 x 109/L Interrupt lenalidomide treatment Return to ≥ 0.5 x 109/L when neutropenia is Resume lenalidomide at Starting dose
prvi put padne na &lt; 0,5 x 109/L privremeno prekinuti liječenje lenalidomidom vrati se na ≥ 0,5 x 109/L, a neutropenija je jedina primijećena toksičnost
FISH analysis ( &gt; /= 200 cells) could be used for post-baseline cytogenetic assessments if &gt; /= 20 metaphases were not available.
FISH analiza ( &gt; /= 200 stanica) može se koristiti za citogenetske procjene nakon početka ako nije bilo dostupno &gt; /= 20 metafaza.
Five days after the last of 15 doses of radiolabelled valnemulin administered to pigs, the concentration in liver was &gt; 6 times that in plasma.
Pet dana nakon posljednjih 15 doza radiooznačenog valnemulina primijenjenih na svinjama koncentracija u jetri bila je za više od 6 puta veća nego u plazmi.
Five of the 6 patients treated with eltrombopag experienced the TEE at a platelet count &gt; 200,000/µl
Pet od 6 bolesnika liječenih eltrombopagom doživjelo je tromboembolijski događaj pri broju trombocita &gt; 200 000/µl.
Five of the 6 patients treated with eltrombopag experienced the thrombotic complication at a platelet count &gt; 200,000/µl and within 30 days of the last dose of eltrombopag.
Pet od 6 bolesnika liječenih eltrombopagom je imalo trombotičke komplikacije pri broju trombocita &gt; 200 000/µl i unutar 30 dana od posljednje doze eltrombopaga.
Five patients had a post-baseline nadir platelet count of &lt; 150,000 cells/mm3, representing a ≥50% decrease in platelets from baseline.
Pet bolesnika imalo je najniži broj trombocita nakon početne vrijednosti od &lt; 150 000 stanica/mm3, što predstavlja smanjenje broja trombocita od ≥50% u odnosu na početnu vrijednost.
Florbetaben (18F) is highly bound to plasma proteins ( &gt; 98.5%).
Florbetaben (18F) se vezuje na bjelančevine plazme s visokim afinitetom ( &gt; 98,5%).
Flu-like symptoms &amp;  *°
Simptomi nalik gripi &amp; 
Flu-like symptoms &amp;  *°
Simptomi nalik gripi &amp;  *°
Flu-like symptoms &amp;  *°
Simptomi nalik gripi &amp;  *º
Fluctuation in serum or plasma concentrations over a dosing interval is low ( &lt; 30 %).
Fluktuacija koncentracija u serumu ili plazmi tijekom intervala doziranja je niska ( &lt; 30%).
Fluctuation in serum or plasma concentrations over a dosing interval is low ( &lt; 30%).
U serumskim ili plazmatskim koncentracijama fluktuacija je niska ( &lt; 30%) tijekom intervala doziranja.
Fluticasone furoate/vilanterol 92/22 micrograms increased adjusted mean weighted mean FEV1 over 0-4 hours by 148 ml compared to FF alone (95% CI: 112, 184 mL, p &lt; 0.001).
Flutikazonfuroat/vilanterol od 92/22 mikrograma povećao je prilagođenu srednju vrijednost ponderiranog srednjeg FEV1 mjerenog od 0-4 sata za 148 ml u odnosu na flutikazonfuroat primijenjen samostalno (95% CI: 112, 184 ml, p &lt; 0,001).
Following 12 weeks of treatment with ledipasvir/sofosbuvir with ribavirin in treatment-experienced patients with compensated cirrhosis (SIRIUS, n = 77), 8/8 patients with baseline NS5A RAVs conferring &gt; 100-fold reduced susceptibility to ledipasvir achieved SVR12.
Nakon 12 tjedana liječenja ledipasvirom/sofosbuvirom s ribavirinom prethodno liječenih pacijenata s kompenziranom cirozom (SIRIUS, n = 77), 8/8 pacijenata s početnim NS5A RAV-ovima koji nose smanjenu osjetljivost na ledipasvir za &gt; 100 puta postiglo je SVR12.
Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change from baseline in modified Total Sharp Score  0.5) was significantly higher with Humira/methotrexate combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and 33.5% respectively, p &lt; 0.001) and Humira monotherapy (50.7%, p &lt; 0.002 and 44.5%, p &lt; 0.001 respectively).
Nakon 52 i 104 tjedna liječenja, postotak bolesnika bez progresije bolesti (promjena ukupnog zbroja bodova prema Sharpu ≤0,5) bio je značajno veći u skupini liječenoj kombinacijom lijeka Humira i metotreksata (63,8% odnosno 61,2%) u usporedbi sa skupinom koja je dobivala monoterapiju metotreksatom (37% odnosno 33,5%, p &lt; 0,001) i monoterapiju lijekom Humira (50,7%, p &lt; 0,002 odnosno 44,5%, p &lt; 0,001).
Following a reduced dose of Teysuno 20 mg/m2 administered once daily to the severe renal impairment group (CrCl &lt; 30 ml/min), the single-dose AUC0-inf and multiple-dose AUC0-τ values for 5-FU were approximately 2-fold higher in the severe renal impairment group compared to those observed in the normal renal function group receiving 30 mg/m2 twice daily.
Nakon smanjenja doze lijeka Teysuno na 20 mg/m2 primijenjene jednom dnevno u skupini bolesnika s teškim oštećenjem bubrega (CrCl &lt; 30 ml/min), vrijednosti AUC0-inf 5-FU-a jednostruke doze i AUC0-t 5- FU-a višestruke doze bile su otprilike dvostruko više u skupini bolesnika s teškim oštećenjem bubrega u usporedbi s vrijednostima opaženima u skupini bolesnika s normalnom bubrežnom funkcijom koja je primala Teysuno u dozi od 30 mg/m2 dva puta na dan.
Following a reduced dose of Teysuno 20 mg/m2 administered once daily to the severe renal impairment group (CrCl &lt; 30 ml/min), the single-dose AUC0-inf and multiple-dose AUC0-τ values for 5-FU were approximately 2-fold higher in the severe renal impairment group compared to those observed in the normal renal function group receiving 30 mg/m2 twice daily.
Nakon smanjenja doze lijeka Teysuno na 20 mg/m2 primijenjene jednom dnevno u skupini bolesnika s teškim oštećenjem bubrega (CrCl &lt; 30 ml/min), vrijednosti AUC0-inf 5-FU-a jednostruke doze i AUC0-t 5- FU-a višestruke doze bile su otprilike dvostruko više u skupini bolesnika s teškim oštećenjem bubrega u usporedbi sa vrijednostima opaženima u skupini bolesnika s normalnom bubrežnom funkcijom koja je primala Teysuno u dozi od 30 mg/m2 dva puta na dan.
Following a single dose of 100 mg [14C]-velpatasvir, the majority ( &gt; 98%) of radioactivity in plasma was parent drug.
Nakon jedne doze od 100 mg [14C]-velpatasvira, većina ( &gt; 98 %) radioaktivnosti u plazmi bila je ishodišni lijek.
Following a single dose of 90 mg [14C]-ledipasvir, systemic exposure was almost exclusively due to the parent drug ( &gt; 98%).
Nakon jedne doze od 90 mg [14C]-ledipasvira, sistemska izloženost bila je gotovo isključivo posljedica izloženosti ishodišnom lijeku ( &gt; 98 %).
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete ( &gt; 90 %) within 24 hours.
Nakon primjene rivastigmina označenog s 14C, eliminacija putem bubrega bila je brza i u osnovi potpuna ( &gt; 90 %) unutar 24 sata.
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete ( &gt; 90%) within 24 hours.
Nakon primjene rivastigmina označenog s 14C, eliminacija putem bubrega bila je brza i u osnovi potpuna ( &gt; 90%) unutar 24 sata.
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete ( &gt; 90%) within 24 hours.
Nakon primjene rivastigmina označenog s 14C-, eliminacija putem bubrega bila je brza i u osnovi potpuna ( &gt; 90%) unutar 24 sata.
Following administration of a single 200 mg IV dose of Sivextro to 8 subjects with severe renal impairment defined as eGFR &lt; 30 mL/min, the Cmax was basically unchanged and AUC0-∞ was changed by less than 10% compared to 8 matched healthy subject controls.
Nakon primjene jednokratne intravenske doze lijeka Sivextro od 200 mg u 8 ispitanika s teškim oštećenjem funkcije bubrega definiranim kao eGFR &lt; 30 ml/min, Cmax je bio u načelu neizmijenjen, a AUC0-∞ je bio izmijenjen za manje od 10% u usporedbi s 8 odgovarajućih zdravih kontrolnih ispitanika.
Following administration of a single dose of lesinurad to individuals with renal impairment compared to those with normal renal function lesinurad Cmax and AUC, respectively, were 36% and 30% higher (200 mg) in patients with mild renal impairment (eCrCL 60 to 89 mL/min), 20% and 73% higher (200 mg) and 3% and 50% higher (400 mg) in patients with moderate renal impairment (eCrCL 30 to 59 mL/min), and 13% higher and 113% higher (400 mg) in patients with severe renal impairment (eCrCL &lt; 30 mL/min).
Nakon primjene jednokratne doze lesinurada u osoba s oštećenjem funkcije bubrega, u usporedbi s onima koji imaju normalnu funkciju bubrega, vrijednosti Cmax odnosno AUC lesinurada bile su 36% odnosno 30% veće (200 mg) u bolesnika s blagim oštećenjem funkcije bubrega (eCrCL 60 do 89 ml/min), 20% odnosno 73% veće (200 mg) i 3% odnosno 50% (400 mg) veće u bolesnika s umjerenim oštećenjem funkcije bubrega (eCrCL 30 do 59 ml/min) te 13% više odnosno 113% veće (400 mg) u bolesnika s teškim oštećenjem funkcije bubrega (eCrCL &lt; 30 ml/min).
Following administration of oral 14C- rivastigmine, renal elimination was rapid and essentially complete ( &gt; 90%) within 24 hours.
Nakon primjene rivastigmina označenog s 14C, eliminacija putem bubrega bila je brza i u osnovi potpuna ( &gt; 90%) unutar 24 sata.
Following booster vaccination, children &gt; 12 months of age are more likely to experience injection site reactions compared to the rates observed in infants during the primary series with Synflorix.
Nakon dodatnog cijepljenja veća je vjerojatnost da će djeca u dobi &gt; 12 mjeseci imati reakcije na mjestu injiciranja u usporedbi sa stopama primijećenima u dojenčadi tijekom primarne serije cijepljenja cjepivom Synflorix.